IP Library › Granted Patent US 12,414,898
Granted Patent B2
US 12,414,898 · App. 18/199,573 · Granted Sep 16, 2025

Therapeutic eye treatment with gases

Inventors: John Berdahl (Sioux Falls, SD); George Tsai (Mission Viejo, CA)
Assignee: Balance Ophthalmics, Inc.
A61H35/02A61B3/102A61F9/0008A61F9/02A61F2009/00891A61H2201/1238A61H2201/165A61H2205/024
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,414,898
App. No.
18/199,573
Granted
Sep 16, 2025
Kind
B2
Abstract

An apparatus to maintain an environment over an anterior surface of a patient eye can include an enclosure sized and shaped to be seated about the patient eye to form a cavity within the enclosure. The enclosure can be configured to contain a fluid other than ambient air in contact with the patient eye. The apparatus can include a fluid regulator in communication with the enclosure, where the fluid regulator can be configured to regulate the composition of the fluid contained within the enclosure.

Claims (27)

1. An apparatus to adjust a fluid humidity level of a fluid in a cavity over an anterior surface of a patient eye, the apparatus comprising:

an enclosure, sized and shaped to form the cavity over the anterior surface of the patient eye, the enclosure including an inlet to receive the fluid and an outlet to return the fluid for recirculation, the cavity configured to contain the fluid for contact with the patient eye;

a pressure source, in communication with the enclosure, configured to transfer the fluid to the inlet and receive the fluid from the outlet; and

a dehumidifier, in communication with the cavity, configured to adjust the fluid humidity level of the fluid in the cavity.

2. The apparatus of claim 1 , further including a humidifier in communication with the cavity.

3. The apparatus of claim 1 , further comprising a processor module with a user interface, in communication with at least one of the pressure source, the humidifier, or the dehumidifier, the processor module configured to allow a user to specify a set point including a fluid humidity level set point.

4. The apparatus of claim 3 , further comprising a humidity sensor in communication with the processor module and the fluid, the humidity sensor configured to sense an indication of the fluid humidity level; and

wherein the processor module is configured to receive the indication of the fluid humidity level and generate a control signal to adjust at least one of the pressure source, the humidifier or a dehumidifier.

5. The apparatus of claim 4 , wherein at least one of the pressure source, the humidifier or the dehumidifier includes a manifold vent configured to introduce an amount of ambient air into the cavity to adjust the fluid humidity level toward the fluid humidity level set point.

6. The apparatus of claim 5 , wherein the control signal is configured to adjust the manifold vent to introduce an amount of ambient air into the cavity to adjust the fluid humidity level toward the fluid humidity level set point.

7. The apparatus of claim 4 , wherein at least one of the pressure source, the humidifier, or the dehumidifier includes a desiccant filter configured for exposure to the fluid to adjust the fluid humidity level toward the fluid humidity level set point.

8. The apparatus of claim 7 , wherein the control signal is configured to adjust a slide valve to regulate fluid flow to the desiccant filter to adjust fluid humidity level toward the fluid humidity level set point.

9. The apparatus of claim 4 , wherein at least one of the pressure source, the humidifier, or the dehumidifier includes a fluid regulator configured to regulate flow of a fluid stored in a reservoir to the cavity to adjust the fluid humidity level.

10. The apparatus of claim 9 , wherein the control signal is configured to adjust the fluid regulator to introduce an amount of the fluid stored in the reservoir to the cavity to adjust fluid humidity level toward the fluid humidity level set point.

11. A method to use an apparatus to adjust a fluid humidity level of a fluid in a cavity over an anterior surface of a patient eye, the apparatus including an enclosure, sized and shaped to form the cavity, the enclosure including an inlet to receive the fluid and an outlet to return the fluid for recirculation, the cavity configured to contain the fluid for contact with the patient eye, a pressure source in communication with the enclosure, configured to transfer the fluid to the inlet and receive the fluid from the outlet, and a dehumidifier in communication with the fluid, configured to adjust the fluid humidity level of the fluid in the cavity, the method comprising:

adjusting the fluid humidity level of the fluid to be delivered to the cavity using the dehumidifier;

delivering the humidity-adjusted fluid to the cavity via an inlet of the enclosure; and

returning the humidity-adjusted fluid from the cavity via the outlet of the enclosure for recirculation using the pressure source.

12. The method of claim 11 , wherein adjusting the fluid humidity level includes decreasing the fluid humidity level in the cavity with the dehumidifier.

13. The method of claim 11 , wherein the apparatus includes a humidifier in communication with the fluid and wherein adjusting the fluid humidity level includes increasing the fluid humidity level in the cavity with the humidifier.

14. The method of claim 13 , wherein at least one of the pressure source, the humidifier, or the dehumidifier includes a manifold vent and decreasing the fluid humidity level includes introducing an amount of ambient air through the manifold vent into the cavity to adjust the fluid humidity level in the cavity.

15. The method of claim 11 , wherein at least one of the pressure source, the humidifier, or the dehumidifier includes a desiccant filter and decreasing the fluid humidity level includes exposing the fluid to the desiccant filter to adjust the fluid humidity level in the cavity.

16. The method of claim 13 , wherein at least one of the pressure source, the humidifier, or the dehumidifier includes a fluid regulator and wherein increasing the fluid humidity level includes regulating flow of a therapeutic fluid stored in a reservoir to the cavity to adjust the fluid humidity level in the cavity.

17. The method of claim 13 , wherein the apparatus further comprises a humidity sensor in communication with the cavity and wherein adjusting the fluid humidity level includes sensing an indication of fluid humidity level in the cavity with the humidity sensor.

18. The method of claim 17 , wherein the apparatus further comprises a processor module with a user interface in communication with at least one of the pressure source, the humidity sensor, the humidifier, or the dehumidifier, and

wherein adjusting the fluid humidity level includes receiving the indication of fluid humidity level in the cavity from the humidity sensor with the processor module and generating a control signal with the processor module to adjust at least one of the pressure source, the humidifier, or the dehumidifier.

19. The method of claim 18 , wherein generating the control signal includes generating a control signal to adjust at least one of the pressure source, the humidifier, or the dehumidifier to change the fluid humidity level of the fluid toward a fluid humidity level set point.

Assignments (4)
CHANGE OF NAME Recorded Oct 3, 2023
From: EQUINOX OPHTHALMIC, INC.
To: BALANCE OPHTHALMICS, INC.
Reel/Frame 065102/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: BERDAHL, JOHN; TSAI, GEORGE
To: EQUINOX, LLC
Reel/Frame 064701/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: EQUINOX, LLC
To: EQUINOX, INC.
Reel/Frame 064701/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: EQUINOX, INC.
To: EQUINOX OPHTHALMIC, INC.
Reel/Frame 064701/0478 →
Continuity (4)
Continuation 17014631 · Sep 8, 2020
Continuation 16083302
Provisional Application 62305751 · Mar 9, 2016
Related Publication 20230363977A1 · Nov 16, 2023
References Cited (166)
US 3010109A · Gray · 1961 [cited by applicant]
US 3426219A · Cancro · 1969 [cited by applicant]
US 4387707A · Polikoff · 1983 [cited by examiner]
US 4429956A · Herbert · 1984 [cited by applicant]
US 4461303A · Refojo et al. · 1984 [cited by applicant]
US 4724843A · Fisher · 1988 [cited by applicant]
US 4907595A · Strauss · 1990 [cited by applicant]
US 4997770A · Giles et al. · 1991 [cited by applicant]
US 5523808A · Kohayakawa · 1996 [cited by applicant]
US 5807357A · Kang · 1998 [cited by applicant]
US 5927281A · Monteleone et al. · 1999 [cited by applicant]
US 5951477A · Ragaluskals et al. · 1999 [cited by applicant]
US 6210000B1 · Yee · 2001 [cited by examiner]
US 6641264B1 · Schhwebel · 2003 [cited by applicant]
US 6673014B2 · Badchi et al. · 2004 [cited by applicant]
US 6908195B2 · Fuller · 2005 [cited by applicant]
US 7833205B2 · Grenon et al. · 2010 [cited by applicant]
US 7981095B2 · Grenon et al. · 2011 [cited by applicant]
US 8408204B2 · Lurie · 2013 [cited by applicant]
US 8758309B2 · Nakamura · 2014 [cited by applicant]
US 8936021B2 · Collins, Jr. · 2015 [cited by applicant]
US 9125724B2 · Berdahl et al. · 2015 [cited by applicant]
US 9445767B2 · Abreu · 2016 [cited by applicant]
US 10799421B2 · Berdahl et al. · 2020 [cited by applicant]
US 20020124843A1 · Skiba et al. · 2002 [cited by applicant]
US 20040237969A1 · Fuller · 2004 [cited by examiner]
US 20060037613A1 · Kwok et al. · 2006 [cited by applicant]
US 20070265505A1 · Guillon et al. · 2007 [cited by applicant]
US 20090247967A1 · Delli, Jr. · 2009 [cited by applicant]
US 20090300829A1 · Spielvogel · 2009 [cited by applicant]
US 20100283956A1 · Jackson et al. · 2010 [cited by applicant]
US 20110022010A1 · Grenon et al. · 2011 [cited by applicant]
US 20120222201A1 · Dondero · 2012 [cited by applicant]
US 20120296261A1 · Whitaker et al. · 2012 [cited by applicant]
US 20130150699A1 · Ostermeier et al. · 2013 [cited by applicant]
US 20130150777A1 · Boehm et al. · 2013 [cited by applicant]
US 20130238015A1 · Berdahl et al. · 2013 [cited by applicant]
US 20130274638A1 · Jennings et al. · 2013 [cited by applicant]
US 20140275935A1 · Walsh et al. · 2014 [cited by applicant]
US 20150313761A1 · Berdahl et al. · 2015 [cited by applicant]
US 20200138669A1 · Berdahl et al. · 2020 [cited by applicant]
US 20200397656A1 · Berdahl et al. · 2020 [cited by applicant]
AU 2017229507B2 · 2020 [cited by applicant]
AU 2022204389A1 · 2022 [cited by applicant]
CN 1559367A · 2005 [cited by applicant]
CN 201182680Y · 2009 [cited by applicant]
CN 102008373A · 2011 [cited by applicant]
CN 102223865A · 2011 [cited by applicant]
CN 102596120A · 2012 [cited by applicant]
CN 202477961U · 2012 [cited by applicant]
CN 202859423U · 2013 [cited by applicant]
CN 103702706A · 2014 [cited by applicant]
CN 203525096U · 2014 [cited by applicant]
CN 203705735U · 2014 [cited by applicant]
CN 104207878A · 2014 [cited by applicant]
CN 204293491U · 2015 [cited by applicant]
CN 104688425A · 2015 [cited by applicant]
CN 204562558U · 2015 [cited by applicant]
CN 104873327A · 2015 [cited by applicant]
CN 105266955A · 2016 [cited by applicant]
CN 109219428A · 2019 [cited by applicant]
CN 209253566U · 2019 [cited by applicant]
CN 112957171A · 2021 [cited by applicant]
DE 19730735A1 · 1999 [cited by applicant]
EP 2392306A1 · 2011 [cited by applicant]
EP 3426219B1 · 2020 [cited by applicant]
EP 3711740A1 · 2020 [cited by applicant]
IN 201817038048A · 2019 [cited by applicant]
JP 2007514493A · 2007 [cited by applicant]
JP 2007517582A · 2007 [cited by applicant]
JP 2019507652A · 2019 [cited by applicant]
JP 6581317B2 · 2019 [cited by applicant]
JP 2019198742A · 2019 [cited by applicant]
JP 2021176591A · 2021 [cited by applicant]
KR 102191309B1 · 2020 [cited by applicant]
WO WO2011013450A1 · 2011 [cited by applicant]
WO WO2015048766A1 · 2015 [cited by applicant]
WO WO2017156050A1 · 2017 [cited by applicant]
WO WVO2018174835A1 · 2018 [cited by applicant]
“Chinese Application Serial No. 202110187610.7, Response filed Mar. 16, 2023 to Office Action mailed Nov. 1, 2022”, w English claims, 8 pgs. [cited by applicant]
U.S. Appl. No. 16/083,302 U.S. Pat. No. 10,799,421, filed Sep. 7, 2018, Therapeutic Eye Treatment With Gases. [cited by applicant]
U.S. Appl. No. 17/014,631 U.S. Pat. No. 11,730,671, filed Sep. 8, 2020, Devices and Methods for Humidity Control Over an Eye (as amended). [cited by applicant]
“U.S. Appl. No. 16/083,302, Notice of Allowance mailed Jun. 10, 2020”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/083,302, Preliminary Amendment Filed Mar. 12, 2020”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 17/014,631, 312 Amendment filed May 15, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 17/014,631, Corrected Notice of Allowability mailed Jul. 20, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 17/014,631, Non Final Office Action mailed Oct. 27, 2022”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 17/014,631, Notice of Allowance malled Feb. 23, 2023”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 17/014,631, PTO Response to Rule 312 Communication mailed May 31, 2023”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 17/014,631, Response filed Jan. 26, 2023 to Non Final Office Action mailed Oct. 27, 2022”, 9 pgs. [cited by applicant]
“Australian Application Serial No. 2017229507, First Examination Report mailed Nov. 14, 2019”, 3 pgs. [cited by applicant]
“Australian Application Serial No. 2017229507, Response filed Jan. 17, 2020 to First Examination Report mailed Nov. 14, 2019”, 22 pgs. [cited by applicant]
“Australian Application Serial No. 2020202299, First Examination Report mailed May 19, 2021”, 4 pgs. [cited by applicant]
“Australian Application Serial No. 2020202299, Response filed Mar. 9, 2022 Subsequent Examiners Report mailed Nov. 11, 2021”, 100 pgs. [cited by applicant]
“Australian Application Serial No. 2020202299, Response filed Sep. 10, 2021 to First Examination Report mailed May 19, 2021”, 6 pgs. [cited by applicant]
“Australian Application Serial No. 2020202299, Subsequent Examiners Report mailed Nov. 11, 2021”. 2 pgs. [cited by applicant]
“Brazilian Application Serial No. 1120180681784, Office Action mailed Dec. 20, 2021”, W/English Translation, 5 pgs. [cited by applicant]
“Brazilian Application Serial No. 1120180681784, Response filed May 6, 2022 to Office Action mailed Dec. 20, 2021”, w/ English claims, 82 pgs. [cited by applicant]
“Canadian Application Serial No. 3,017,154, Non Final Office Action mailed May 3, 2022”, 5 pgs. [cited by applicant]
“Canadian Application Serial No. 3,017,154, Office Action mailed Apr. 23, 2021”, 4 pgs. [cited by applicant]
“Canadian Application Serial No. 3,017,154, Office Action mailed Oct. 2, 2019”, 4 pgs. [cited by applicant]
“Canadian Application Serial No. 3,017,154, Office Action mailed Oct. 12, 2021”, 4 pgs. [cited by applicant]
“Canadian Application Serial No. 3,017,154, Response filed Feb. 8, 2022 to Office Action mailed Oct. 12, 2021”, 26 pgs. [cited by applicant]
“Canadian Application Serial No. 3,017,154, Response filed Apr. 2, 2020 to Office Action mailed Oct. 2, 2019”, 16 pgs. [cited by applicant]
“Canadian Application Serial No. 3,017,154, Response filed Aug. 17, 2021 to Office Action mailed Apr. 23, 2021”, 26 pgs. [cited by applicant]
“Canadian Application Serial No. 3,017,154, Response filed Aug. 31, 2022 to Non Final Office Action mailed May 3, 2022”, 9 pgs. [cited by applicant]
“Canadian Application Serial No. 3,017,154, Voluntary Amendment filed Jan. 27, 2021”, 16 pgs. [cited by applicant]
“Cataract Surgery to Lower Intraocular Pressure”, Middle East African Journal of Ophthalmology, 16 (3), (Sep. 2009), 1-5. [cited by applicant]
“Chinese Application Serial No. 201780028637.3, Office Action mailed Apr. 7, 2020”, w/ English Translation, 17 pgs. [cited by applicant]
“Chinese Application Serial No. 201780028637.3, Response filed Oct. 22, 2020 to Office Action mailed Apr. 7, 2020”, w/ English Claims, 10 pgs. [cited by applicant]
“Chinese Application Serial No. 201780028637.3, Response to Examiner Telephone Interview filed Nov. 6, 2020”, w/ English Claims, 7 pgs. [cited by applicant]
“Chinese Application Serial No. 202110187610.7, Office Action mailed Jun. 14, 2023”, w/ English translation, 20 pgs. [cited by applicant]
“Chinese Application Serial No. 202110187610.7, Office Action mailed Nov. 1, 2022”, w/ English Translation, 17 pgs. [cited by applicant]
“Drug Absorption and Disposition in the Eye”, Review on Ocular Drug Delivery / Pharma Tutor, [Online]. Retrieved from the Internet: <URL: http://www.pharmatutor.org/articles/reviewonoculardrugdelivery?page=0,3, (Sep. 19… [cited by applicant]
“European Application Serial No. 17712612.5, Response Filed Oct. 16, 2018 to Communication pursuant to Rules 161(1) and 162 EPC mailed Oct. 16, 2018”, w/ English Claims, 12 pgs. [cited by applicant]
“European Application Serial No. 20159377.9, Communication Pursuant to Article 94(3) EPC mailed Apr. 11, 2022”, 7 pgs. [cited by applicant]
“European Application Serial No. 20159377.9, Extended European Search Report mailed Aug. 13, 2020”, 10 pgs. [cited by applicant]
“European Application Serial No. 20159377.9, Response filed Mar. 23, 2021 to Extended European Search Report mailed Aug. 13, 2020”, 14 pgs. [cited by applicant]
“Eyemate”, IOP GmbH, [Online]. Retrieved from the Internet: <URL: http://www.implandata/com/eyemate.html>, (Accessed Oct. 9, 2015), 2 pgs. [cited by applicant]
“Indian Application Serial No. 201817038048, First Examiners Report mailed Jan. 14, 2020”, w/ English Translation, 7 pgs. [cited by applicant]
“Indian Application Serial No. 201817038048, Response filed Apr. 15, 2020 to First Examiners Report mailed Jan. 14, 2020”, 61 pgs. [cited by applicant]
“Indian Application Serial No. 201817038048, Voluntary Amendment filed Dec. 7, 2018”, w/English Claims, 12 pgs. [cited by applicant]
“International Application Serial No. PCT/US2017/021240, International Preliminary Report on Patentability mailed Sep. 20, 2018”, 8 pgs. [cited by applicant]
“International Application Serial No. PCT/US2017/021240, International Search Report mailed Jun. 20, 2017”, 8 pgs. [cited by applicant]
“International Application Serial No. PCT/US2017/021240, Written Opinion mailed Jun. 20, 2017”, 6 pgs. [cited by applicant]
“Japanese Application Serial No. 2019-156790, Notification of Reasons for Refusal mailed Mar. 16, 2021”, w/English Translation, 8 pgs. [cited by applicant]
“Japanese Application Serial No. 2019-156790, Response filed Jun. 16, 2021 to Office Action mailed Mar. 16, 2021”, w/ English claims, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2019-156790, Voluntary Amendment filed Mar. 6, 2020”, w/ English Claims, 5 pgs. [cited by applicant]
“Japanese Application Serial No. 2021-128243, Notification of Reasons for Rejection mailed May 31, 2022”, W/English Translation, 6 pgs. [cited by applicant]
“Korean Application Serial No. 10-2018-7029058, Notice of Preliminary Rejection mailed Feb. 14, 2020”, w/ English Translation, 5 pgs. [cited by applicant]
“Korean Application Serial No. 10-2018-7029058, Response filed Mar. 31, 2020 to Notice of Preliminary Rejection mailed Feb. 14, 2020”, w/ English Claims, 12 pgs. [cited by applicant]
“Korean Application Serial No. 10-2020-7035258, Final Office Action mailed Sep. 15, 2021”, w/ English translation, 8 pgs. [cited by applicant]
“Korean Application Serial No. 10-2020-7035258, Notice of Preliminary Rejection mailed Feb. 24, 2021”, w/English Translation, 9 pgs. [cited by applicant]
“Korean Application Serial No. 10-2020-7035258, Response filed May 21, 2021 to Notice of Preliminary Rejection mailed Feb. 24, 2021”, w/ English claims, 16 pgs. [cited by applicant]
“Korean Application Serial No. 10-2022-7012723, Notice of Preliminary Rejection mailed Jul. 1, 2022”, w/ English translation, 7 pgs. [cited by applicant]
“Mexican Application Serial No. MX/a/2018/010860, Office Action mailed Jun. 23, 2022”, w/o English translation, 3 pgs. [cited by applicant]
“Non-Invasive Oxygen Sensors”, [Online]. Retrieved from the Internet: <URL; http://www.presens.de/fileadmin/user_upload/products/Sensor_Probes/Noninvasive_oxygen_sensors/150205_SP-NonInvOx-15-01_w.pdf, (Accessed Mar. 8,… [cited by applicant]
Alexander, David J., et al., “Risk of Spaceflight-Induced Intracranial Hypertension and Vision Alterations”, Evidence Report—Version 1.0, (Jul. 12, 2012), 109 pgs. [cited by applicant]
Allin, David, et al., “Laboratory Testing of the Pressio Intracranial Pressure Monitor”, Neurosurgery, vol. 62, vol. 5, [Online]. Retrieved from the Internet: <URL: www.neurosurgery-online.com, (May 2008), 1158-1161. [cited by applicant]
Araci, Ismail E., “An implantable microfuidic device for self-monitoring of intraocular pressure”, nature medicine, vol. 20, No. 9—Technical Reports, (Sep. 2014), 1074-1080. [cited by applicant]
Berdahl, et al., “Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma”, Ophthalmology 115(5), (May 2008), 763-768. [cited by applicant]
Berdahl, John P., et al., “Body Mass Index Has a Linear Relationship with Cerebrospinal Fluid Pressure”, IOVS, vol. 53, No. 3, (Mar. 2012), 1422-1427. [cited by applicant]
Berdahl, John P., et al., “Intracranial pressure and glaucoma”, Current Opinion in Ophthalmology 21-, (2010), 106-111. [cited by applicant]
Berdahl, John P., et al., “Intracranial Pressure in Primary Open Angle Glaucoma, Normal Tension Glaucoma, and Ocluar Hypertension: A Case-Control Study”, IOVS, vol. 49, No. 12, (Dec. 2008), 5412-5418. [cited by applicant]
Berdahl, John P., “Recovery of Corneal Hysteresis after Reduction of Intraocular Pressure in Chronic Primary Angle-Closure Glaucoma”, American Journal of Ophthalmolog—Correspondence, (Oct. 2009), 623-624. [cited by applicant]
Berdahl, John P., “Systemic Parameters Associated With Cerebrospinal Fluid Pressure”, J Glaucoma, vol. 22, No. 5, Suppl 1, [Online]. Retrieved from the Internet: <URL: www.glaucomajournal.com, (Jul. 2013), S17-S18. [cited by applicant]
Berdahl, John P., “The translaminar pressure gradient in sustained zero gravity, idiopathic inracranial hypertension and glaucoma”, Medical Hypotheses 79, (2012), 719-724. [cited by applicant]
Ersanli, D/, et al., “The effect of hyperbaric oxygen on intraocular pressure”, UHM vol. 33, No. 1, (2006), 1-4. [cited by applicant]
Fleischman, David, et al., “Cerebrospinal Fluid Pressure Decreases with Older Age”, PLOS One, vol. 7, Issue 12, [Online]. Retrieved from the Internet: < URL: www.plosone.org, (Dec. 2012), 1-9. [cited by applicant]
Fleischman, David, et al., “Increasing intraocular pressure as treatment for papilledema”, Experimental Eye Research 115, (2013), 278. [cited by applicant]
Gallin-Cohen, Pamela F., et al., “Oxygen lowers intraocular pressure”, Invest. Ophthalmol. Vis. Sci, (Jan. 1980), 43-48. [cited by applicant]
Guadana, Ripal, et al., “Ocular Drug Delivery”, The AAPS Journal, vol. 12, No. 3, (Sep. 2010), 348/-360. [cited by applicant]
Hayreh, Sohan Singh, “Cerebrospinal fluid pressure and glaucomatous optic disc cupping (response to Berdahl and colleagues)”, Graefes Arch Clin Exp Opthtalmol, 247, (2009), 1291-1294. [cited by applicant]
Hillen, Mark, “In Practice (VIIP: A Space Odyssey)”, The Ophthalmologist , vol. 11, (Sep. 2014), 6 pgs. [cited by applicant]
Kwon, Oh Seok, et al., “Flexible FET-Type VEGF Aptasensor Based on Nitrogen-Doped Graphene Converted from Conducting Polymer”, ACS Nano, vol. 6, No. 2, (2012), 1486-1493. [cited by applicant]
Lalwani, K, et al., “The effect of nitrous oxide on intra-ocular pressure in healthy adults”, Anaesthesia 2012, 67, (2012), 256-260. [cited by applicant]
Melki, Samir, et al., “An implantable Intraocular Pressure Transducer Initial Safety Outcomes”, JAMA Ophthalmology, [Online]. Retrieved from the Internet: <URL: http://archopht.jamanetwork.com/, (Jun. 26, 14), E1-E5. [cited by applicant]
Muenster, Stefan, et al., “The Ability of Nitric Oxide to Lower Intraocular Pressure Is Dependent on Guanylyl Cyclase”, Investigative Ophthalmology & Visual Science, vol. 58, No. 11. (Sep. 2017), 4826-4835. [cited by applicant]
Niwa, Yoshiaki, et al., “A New System to Supply Carbon Dioxide Safely to Glaucoma Patients”, Jpn J Ophthalmol 43, (1999), 16-19. [cited by applicant]
Paschalis, Eleftherios, et al., “Reliable intraocular pressure meausrement using automated radio-wave telemetry”, Clinical Ophthalmology 2014: 8, (2014), 177-185. [cited by applicant]
Patane, Michael, et al., “Ocular lontophoresis for Drug Delvery”, Retina Today, (Mar. 2011). 64-66. [cited by applicant]
Samuel, J. R., et al., “Effect Of carbon dioxide on the intraocular pressure in man during general anaethesia”, Brit. J. Ophthal 58,62, [Online]. Retrieved from the Internet: <URL: http://bjo.bmj.com/, (1974), 62-67. [cited by applicant]
Singh, Daljit, “Fuchs Endothelial Dystrophy Treatment & Management—Medical Care”, (Aug. 19, 2014), 3 pgs. [cited by applicant]
Song, Shiping, et al., “Aptamer-based biosensors”, Trends in Analytical Chemistry, vol. 27, No. 2, (2008), 108-117. [cited by applicant]
Yeoh, Ronald, “Hydrorupture of the posterior capsule in femtosecond-laser cataract surgery”, J Cataract Refract Surg, vol. 38, (Apr. 2012), 730-731. [cited by applicant]
Yoo, Eun-Hyung, et al., “Glucose Biosensors: An Overview of Use in Clinical Practice”, Sensors 10, (2010), 4558-4576. [cited by applicant]